Recent developments in patented DC-based immunotherapy for various malignancies

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Dendritic cells (DCs) play a crucial role in maintaining the immune system. DC-based immunotherapy is known as the "cancer vaccine" for advanced cancers and to prevent recurrence. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, its clinical efficacies in many human trials are still insufficient. To identify the causes of these low efficacies, many investigators have focused on the numbers of administered DCs, how they are activated, which type is best, and so on. This review focuses primarily on patents analysis of recently developed DC-based cancer immunotherapies. We also analyze the critical factors of DC-based cancer immunotherapy to best optimize the development of these novel technologies.

Original languageEnglish
Pages (from-to)72-87
Number of pages16
JournalRecent Patents on Regenerative Medicine
Issue number1
Publication statusPublished - Jan 2011

All Science Journal Classification (ASJC) codes

  • Developmental Neuroscience
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'Recent developments in patented DC-based immunotherapy for various malignancies'. Together they form a unique fingerprint.

Cite this